secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001576885-24-000090
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q2 net loss expands to $20.5M; Phase 2 AD trial enrollment ahead of expectations
--------------------------------------------------------------------------------

- Net loss $20.5M in Q2 2024 vs $11.6M in Q2 2023; R&D spending rose to $19.5M (from $9.1M) on ALTITUDE-AD costs.
- Cash, equivalents, and securities $281.4M at June 30, 2024 (down from $306.1M at Dec 31, 2023); runway into H1 2027.
- Phase 2 ALTITUDE-AD enrollment faster than expected; over 50 sites activated in U.S., Canada, U.K., EU.
- Phase 1 subcutaneous sabirnetug study dosed first subject July 2024; topline data expected Q1 2025.
- Virtual R&D Day planned Oct 2, 2024, to detail sabirnetug science and Phase 1 results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000090/0001576885-24-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688524000090/abos-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001576885-24-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer